ClinicalTrials.gg
RecruitingNCT07397819Updated Feb 9, 2026

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

A Phase 1/2 interventional study of liposomal irinotecan monotherapy and liposomal irinotecan monotherapy in Malignant Ascites, sponsored by Dong sheng Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Dong sheng Zhang · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ascites with a site in China — 14 open to participants now, 16 under way, 1 of them phase 3. Ascites · China.

Planned enrollment
19th of 37
48 · median 48
Started
2025
with 1 other
Phase 1/2
4 of 43
3 open now
Primary completion
2028-06
later than 13 of 15 live
Registered
40th of 43
by date

Among the 43 studies in Ascites with a site in China, this one is the 19th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 13 of the 15 other live ones, and was the 40th registered.

Ascites

248 studies on the registry are indexed under Ascites; 57 are open to participants now.

Browse Ascites studies →

Open to participants now

14 of the 43 studies in Ascites with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ascites with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multi-cohort Phase Ib/II clinical trial, consisting of two stages as follows:

  1. Phase Ib Dose-Escalation Stage To explore the dose-limiting toxicities (DLT) of intraperitoneally administered liposomal irinotecan in patients with malignant peritoneal effusion who have failed prior standard therapy, and to estimate the maximum tolerated dose (MTD) of the investigational agent.
  2. Phase II Expansion Stage To evaluate the efficacy and safety of liposomal irinotecan as monotherapy or in combination with recombinant modified human tumor necrosis factor or bevacizumab, in the treatment of malignant peritoneal effusion in patients who have failed prior standard therapy.
03

Conditions studied

  • Malignant Ascites

Browse trials for

Keywords

  • Liposomal Irinotecan
  • Recombinant Mutant Human Tumor Necrosis Factor
  • Bevacizumab
  • Malignant Ascites
  • Intraperitoneal Injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years old, gender unrestricted.
  • or cytologically confirmed malignant peritoneal effusion derived from digestive system tumors ( confirmed by ascites cytology, or peritoneal diagnosed clinically based on imaging findings and symptoms).
  • Moderate to large volume of peritoneal effusion, with failure of initial treatment or previous intraperitoneal therapy with conventional chemotherapeutic agents and/or biological response modifiers. Moderate volume of ascites is defined as: ①Ascites depth ≥3 cm confirmed by supine abdominal ultrasound; ② Presence of clinical symptoms (chest distress, dyspnea, abdominal distension and discomfort) judged by the investigator to be related to peritoneal effusion.
  • performance status score 0-2.
  • Expected survival time >3 months.
  • Essentially normal cardiopulmonary function.
  • Adequate organ function, with subjects required to meet the following laboratory parameters:

    1. Peripheral blood count: WBC ≥4.0×10⁹/L, ≥80×10⁹/L, ≥90 g/L.
    2. Renal function: Serum creatinine ≤2× and rate (calculated by the Cockcroft-Gault formula) ≥40 ml/min.
    3. Hepatic function: Total ≤1.5×ULN; or total bilirubin >ULN with direct bilirubin ≤ULN. (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (for patients with liver metastases, ALT or AST ≤5×ULN is acceptable).
    4. Adequate coagulation function, defined as (INR) or prothrombin time (PT) ≤1.5×ULN.
  • Thyroid stimulating hormone (TSH) ≤ULN. If TSH is abnormal, serum triiodothyronine (T3) and thyroxine (T4) levels, together with clinical manifestations, shall be evaluated comprehensively; subjects in non-acute active phase are eligible for enrollment.
  • For non-surgically sterilized subjects of or female subjects of childbearing potential: A medically approved method (e.g., intrauterine device, oral contraceptives, or condoms) must be used during the study treatment period and for 6 months after the end of study treatment. For non-surgically sterilized female subjects of childbearing potential, serum or urine HCG test must be negative within 7 days prior to enrollment, and they must be non-lactating. For male subjects whose partners are women of childbearing potential, effective contraceptive measures must be adopted during the trial and for 6 months after the last administration of the study drug.
  • Voluntarily participate in the study with good compliance, sign a written form, and be able to cooperate with follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • History of to tumor necrosis factor (TNF), its derivative drugs, bevacizumab or its analogs, irinotecan, or liposomal irinotecan.
  • Diagnosis of malignant diseases other than gastrointestinal tumors within 5 years prior to the first dose (excluding radically treated basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and/or radically resected carcinoma in situ).
  • Receipt of any other drug treatment or participation in an interventional clinical trial within 7 days prior to the first dose; or receipt of anti-tumor therapy (including Chinese herbal medicines with anti-tumor indications) within 7 days prior to the first dose of the study drug.
  • Pregnant or lactating women; women of who are unwilling to take measures during the study period; or men who are unwilling to use effective contraceptive measures during treatment and for 1 year thereafter.
  • Significant impairment of major organ function.
  • Patients with obvious bleeding tendency.
  • or uncontrolled cardiac diseases, including unstable angina pectoris, acute myocardial infarction within 6 months prior to the first dose, (NYHA) Class III/IV congestive heart failure, and uncontrolled arrhythmias (subjects with pacemakers or atrial fibrillation with well-controlled heart rate are permitted).
  • Clinically significant abnormalities or relevant medical history as judged by the investigator; screening interval > 480 ms. For subjects with intraventricular conduction block (QRS interval > 120 ms), JTc interval may be used instead of QTc interval (if JTc is used, it must be ≤ 340 ms).
  • Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg despite optimal medical treatment; a history of hypertensive crisis or hypertensive encephalopathy.
  • Severe acute infection that is uncontrolled; current fever (> 38℃), purulent or chronic infection, or unhealed wounds.
  • Patients with radiologically confirmed loculated peritoneal effusion; definitely diagnosed peritoneal infection.
  • Active acute or chronic or C infection, with hepatitis B virus (HBV) DNA > 2000 IU/mL or 10⁴ copies/mL; virus (HCV) RNA > 10³ copies/mL; concurrent positivity for hepatitis B surface antigen (HBsAg) and anti-HCV antibody. Subjects who have received nucleoside analog antiviral therapy and achieved viral load below the above thresholds are eligible for enrollment. A known history of (HIV) infection or confirmed positive HIV test results.
  • Evidence or history of obvious bleeding tendency within 3 months prior to enrollment (bleeding > 30 mL within 3 months, hematemesis, melena, hematochezia); hemoptysis (> 5 mL of fresh blood within 4 weeks); a history of hereditary or acquired bleeding disorders or coagulation dysfunction. Clinically significant bleeding symptoms or definite bleeding tendency within 3 months prior to enrollment (e.g., gastrointestinal bleeding, hemorrhagic gastric ulcer).
  • A history of arterial or venous thrombotic disease within 6 weeks prior to enrollment.
  • A known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  • Receipt of major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment, or anticipated need for major surgery during the study treatment period.
  • Failure to achieve adequate recovery from toxicity and/or complications of major surgery prior to the start of treatment.
  • Pregnant or lactating women; or subjects who plan to conceive or give birth during the study period from screening visit to completion of safety follow-up visit (90 days after the last dose for male subjects).
  • Receipt of radiotherapy within 4 weeks prior to the first dose of study drug.
  • Radiotherapy-related toxicities in subjects must have fully resolved, without the need for therapy, and radiation pneumonitis must be definitely excluded. For palliative radiotherapy for non-central nervous system (CNS) diseases, a 2-week is permitted.
  • Uncontrolled neurological or psychiatric diseases/disorders with poor compliance, resulting in inability to cooperate or report treatment responses. Uncontrolled primary brain tumors or central nervous system with obvious intracranial hypertension or neuropsychiatric symptoms.
  • Other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Phase Ib Dose-Escalation Stage

    Drug: liposomal irinotecan monotherapy

  • Experimental
    Phase II Expansion Stage-ARM A

    Drug: liposomal irinotecan monotherapy

  • Experimental
    Phase II Expansion Stage-ARM B

    Drug: Liposomal Irinotecan + rmhTNF-NC

  • Experimental
    Phase II Expansion Stage-ARM C

    Drug: Liposomal Irinotecan + Bevacizumab

Interventions

  • Drugliposomal irinotecan monotherapy

    A "3+3" dose-escalation design will be adopted. A total of 9-18 eligible subjects will receive liposomal irinotecan treatment, with three predefined dose levels as follows: Dose Level 1: 20 mg, intraperitoneal injection (ip), administered on Day 1, Day 8, Day 15, and Day 21. Dose Level 2: 30 mg, intraperitoneal injection (ip), administered on Day 1, Day 8, Day 15, and Day 21. Dose Level 3: 40 mg, intraperitoneal injection (ip), administered on Day 1, Day 8, Day 15, and Day 21. Each subject will receive only one treatment cycle. The dosage of liposomal irinotecan will be escalated gradually from the lowest dose level to the highest. Dose-limiting toxicities (DLT) will be monitored throughout the administration cycle. Each subject will receive only one dose level of liposomal irinotecan during the study period. All subjects will complete the relevant tests specified in the protocol during treatment to evaluate safety and preliminary efficacy. Subsequent treatment regimens will be selecte

  • Drugliposomal irinotecan monotherapy

    Liposomal irinotecan (at RP2D, intraperitoneal injection \[ip\], administered on Day 1, Day 8, Day 15 and Day 21).

  • DrugLiposomal Irinotecan + rmhTNF-NC

    Liposomal Irinotecan (at RP2D dose, ip, D1, D8, D15, D21) rmhTNF-NC (300 IU per administration, ip, D1, D8, D15)

  • DrugLiposomal Irinotecan + Bevacizumab

    Drug pages: IrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liposomal Irinotecan (at RP2D dose, ip, D1, D8, D15, D21) Bevacizumab (100 mg, ip, D1, D15)

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Defined as the highest dose at which less than 33% of subjects experience dose-limiting toxicity (DLT).

    Time frame: 4 weeks after administration

  2. Objective Response Rate

    The proportion of subjects achieving complete response and partial response per WHO criteria.

    Time frame: Up to 4 weeks after the first cycle

Secondary outcomes

  1. Duration of Response

    The time interval from the first documentation of objective response in malignant ascites, to the first documentation of disease progression of ascites or death due to any cause, evaluated per the WHO criteria for malignant ascites.

    Time frame: from the first documentation of CR/PR to PD/death, up to 1 year

  2. Disease control rate

    The proportion of subjects achieving complete response, partial response, or stable disease in malignant ascites, evaluated per the WHO criteria.

    Time frame: 4 weeks after first treatment cycle

  3. Safety and Tolerability

    The severity of adverse events will be graded and assessed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0,

    Time frame: through study completion, an average of 1 year

  4. Quality of Life

    Assessment will be performed using the Chinese version of the Functional Assessment of Chronic Illness Therapy-Ascites Index (FACIT-AI) to evaluate the impact of malignant ascites and treatment on patients' physical function, symptom burden, and daily living ability.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Feb 9, 2026
StartActual
Nov 28, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07397819
Lead sponsor
Dong sheng Zhang
Collaborators
CSPC Pharmaceutical Group Limited
Responsible party
Dong sheng Zhang (Chief Physician, Sun Yat-sen University) — Sponsor-investigator
First posted
Feb 9, 2026
Start date
Nov 28, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Feb 9, 2026

Study contacts

Zhang Dongsheng
Contact
zhangdsh@sysucc.org.cn
13719437860
Wang Yingnan
Contact
15521145855

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Bevacizumab

Start the discussion